Skip to main content
. 2022 Sep 8;131(5):325–346. doi: 10.1111/bcpt.13782
Human clinical trials
Study participants n > 100
Measurement of the participants' DPYD‐genotype
Treatment with systemic treatment with 5‐FU, Capcitabin or Tegafur (teysuno),
Data regarding adverse events after treatment
Cancer treatment